NEW YORK, June 16 /PRNewswire-FirstCall/ -- Paradigm Genetics
(Nasdaq: PDGM) today announced that Heinrich Gugger, Ph.D., President and
Chief Executive Officer, will provide an overview of the Company at the
Needham & Company Third Annual Biotech Conference at The New York Palace Hotel
in New York City on Thursday, June 17, 2004. To access the live audio webcast,
visit the Company's website at http://www.ParadigmGenetics.com . The webcast will be
archived for 90 days following the presentation.
Conference: Needham & Company Third Annual Biotech Conference
Date: Thursday, June 17, 2004
Time: 11:30 a.m., ET
Place: The New York Palace Hotel
455 Madison Avenue, New York, NY 10022
About Paradigm Genetics
Paradigm Genetics is a biotechnology company applying its proprietary
systems biology platform to the discovery of safer, more effective drugs and
agrichemicals. Paradigm Genetics has major collaborations with the National
Institute of Environmental Health Sciences, Bayer CropScience, the Monsanto
Company, Pioneer Hi-Bred International, the National Institute of Standards &
Technology's Advanced Technology Program, and L'Oreal Inc. For more
information, visit http://www.ParadigmGenetics.com .
This press release contains forward-looking statements, including
statements regarding the Company's expectations for using its systems biology
platform to discover safer, more effective drugs and agrichemicals. Such
forward-looking statements are based on management's current expectations and
are subject to a number of risks, factors and uncertainties that may cause
actual results, events and performance to differ materially from those
referred to in the forward-looking statements. These risks, factors and
uncertainties include, but are not limited to, Paradigm's early stage of
development, history of net losses, technological and product development
uncertainties, reliance on research collaborations, uncertainty of additional
funding and ability to protect its patents and proprietary rights. Certain of
these and other risks are identified in Paradigm's annual report on Form 10-K
for the year ended December 31, 2003 and in its quarterly report on Form 10-Q
for the quarter ended March 31, 2004, each filed with the Securities and
Exchange Commission. The Company does not intend to update any of the forward-
looking statements after the date of this release to conform these statements
to actual results or to changes in our expectations, except as may be required
by law.
SOURCE Paradigm Genetics
 back to top
Related links:
http://www.paradigmgenetics.com
CONTACT:
Brian Ritchie or Mark Vincent of Euro RSCG
Life NRP, +1-212-845-4200
|
